Dietary supplementation of clinically utilized PI3K p110α inhibitor extends the lifespan of male and female mice.
C P HedgesB ShettySophie C BroomeC MacRaeP KoutsifeliEmma J BuckelsC MacIndoeJ BoixT TsiloulisB G MatthewsS SinhaM ArendseJ K JaiswalK M MellorA J R HickeyP R ShepherdTroy L MerryPublished in: Nature aging (2023)
Diminished insulin and insulin-like growth factor-1 signaling extends the lifespan of invertebrates 1-4 ; however, whether it is a feasible longevity target in mammals is less clear 5-12 . Clinically utilized therapeutics that target this pathway, such as small-molecule inhibitors of phosphoinositide 3-kinase p110α (PI3Ki), provide a translatable approach to studying the impact of these pathways on aging. Here, we provide evidence that dietary supplementation with the PI3Ki alpelisib from middle age extends the median and maximal lifespan of mice, an effect that was more pronounced in females. While long-term PI3Ki treatment was well tolerated and led to greater strength and balance, negative impacts on common human aging markers, including reductions in bone mass and mild hyperglycemia, were also evident. These results suggest that while pharmacological suppression of insulin receptor (IR)/insulin-like growth factor receptor (IGFR) targets could represent a promising approach to delaying some aspects of aging, caution should be taken in translation to humans.
Keyphrases
- small molecule
- type diabetes
- neoadjuvant chemotherapy
- high fat diet induced
- endothelial cells
- glycemic control
- growth hormone
- heart rate
- protein protein
- wild type
- skeletal muscle
- protein kinase
- adipose tissue
- induced pluripotent stem cells
- soft tissue
- pluripotent stem cells
- blood pressure
- insulin resistance
- lymph node
- weight loss